Sprycel (dasatinib), a leukemia medication raises the risk of developing pulmonary arterial hypertension, the US Food and Drug Administration (FDA) announced today in a Drug Safety Communication. The FDA says doctors should check patients for signs and symptoms of underlying cardiopulmonary disease before considering prescribing Sprycel - they should also evaluate patients during treatment. Pulmonary arterial hypertension, also known as pulmonary hypertension or PAH is a kind of high blood pressure that only affects the arteries in the lung and the right side of the patient's heart... Read from Source
